Foghorn Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
FHTX$1.90-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(19,875) | $(18,834) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,383 | 2,692 |
| Depreciation and amortization expense | 238 | 827 |
| Noncash lease expense | 561 | 1,449 |
| Accretion of discount on marketable securities | (388) | (818) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (91) | 1,069 |
| Accounts payable | (990) | 284 |
| Accrued expenses and other liabilities | (4,458) | (2,407) |
| Operating lease liabilities | 621 | (2,279) |
| Deferred revenue | (3,267) | (5,951) |
| Net cash used in operating activities | (25,266) | (23,968) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (28) |
| Purchases of marketable securities | (66,938) | (51,124) |
| Proceeds from maturities of marketable securities | 49,219 | 80,553 |
| Net cash provided by (used in) investing activities | (17,719) | 29,401 |
| Cash flows from financing activities: | ||
| Proceeds from offerings of common stock, pre-funded warrants, and series warrants net of underwriting discounts and commissions | 49,999 | — |
| Payments of public offering costs | (316) | — |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 89 | 139 |
| Net cash provided by financing activities | 49,772 | 139 |
| Net increase in cash, cash equivalents and restricted cash | 6,787 | 5,572 |
| Cash, cash equivalents and restricted cash at beginning of period | 84,126 | 57,162 |
| Cash, cash equivalents and restricted cash at end of period | $90,913 | $62,734 |
| Supplemental disclosure and noncash investing and financing information: | ||
| Cash paid for taxes | $2 | $4 |
| Purchases of property and equipment included in accounts payable and accrued expenses | $35 | $— |
| Public offering costs in accounts payable and accrued expenses | $31 | $— |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $87,663 | $61,026 |
| Restricted cash | 3,250 | 1,708 |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $90,913 | $62,734 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.